Selpercatinib Aimed atRET-Altered Cancers

A remarkable increase has occurred in the number of highly targeted drugs that have efficacy in patients with advanced cancers that harbor specific genomic alterations. Prime examples are the NTRK inhibitors that target NTRK fusions, which are found in only approximately 0.3% of cancers.1,2 As many as 75% of the patients with tumors that bear NTRK fusions and who have received these agents have had a response. These results have led to the Food and Drug Administration (FDA) approval of the use of the NTRK inhibitors larotrectinib and entrectinib in adult and pediatric patients with NTRK fusion–positive solid tumors, regardless . . .